Arzanya and leadXpro collaborate on  exploring macrocycle discovery on membrane proteins 

Arzanya and leadXpro AG announce a partnership to explore the potential for combining their specific technology platforms and knowledge to discover macrocyclic ligands binding to membrane protein drug targets. 

The collaboration will combine Arzanya’s high-throughput yeast display screening platform for the selection of peptide macrocycles with leadXpro’s expertise in membrane protein generation, structure determination and application of biophysical methods to investigate the potential for discovering novel ligands against challenging membrane protein drug targets. 

Michael Hennig, leadXpro: “We’re excited to complement our capabilities with the novel technology of Arzanya in yeast display macrocyclic peptide discovery to expand the druggable target space.”  

Alessandro Angelini, Arzanya: “We are thrilled to partner with leadXpro, a global leader in GPCR research, to advance our platform and unlock the potential of macrocyclic peptides against challenging pharmaceutical targets”. 

For more information, please visit:
www.arzanya.com 
www.leadxpro.com